Dept of Pharma implementing PLI Scheme for Pharma at cost of Rs 15,000 cr
New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28, Ministry of Chemicals and Fertilizers informed Lok Sabha on Friday.
The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years, Union Minister of State for Chemicals and Fertilizers Anupriya Patel informed the Lok Sabha in response to a question.
The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc.
Orphan drugs are those drugs which are used for treatment of rare diseases.
Under the scheme, a total of eight orphan drugs have been approved for manufacturing.
The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
- Nitisinone used for treatment of Hereditary Tyrosinemia Type 1
- Nusinersen used for treatment of Spinal Muscular Atrophy
- Rufinamide used for treatment of Lennox-Gastaut syndrome.
- Sodium Phenyl Butyrate used for treatment of Urea Cycle Disorders
- Tiopronin used for Prevention of Cystine Nephrolithiasis
- Trientine Hydrochloride used for treatment of Wilson's disease
- Eliglustat used for treatment of Gaucher’s disease
- Cannabidiol used for treatment of Dravet-Lennox Gastaut syndrome
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
